Distinct clinical courses of epithelial ovarian cancer with mutations in BRCA1 5’ and 3’ exons

Kyung Jin Eoh; Hyung Seok Park; Ji Soo Park; Seung Tae Lee; Jung Woo Han; Jung Yun Lee; Sunghoon Kim; Sang Wun Kim; Young Tae Kim; Eun Ji Nam

doi:10.21873/anticanres.13073

Distinct clinical courses of epithelial ovarian cancer with mutations in BRCA1 5’ and 3’ exons

Kyung Jin Eoh, Hyung Seok Park, Ji Soo Park, Seung Tae Lee, Jung Woo Han, Jung Yun Lee, Sunghoon Kim, Sang Wun Kim, Young Tae Kim, Eun Ji Nam

Department of Obstetrics and Gynecology

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Background/Aim: This study aimed to determine the effect of different BRCA1 exonal mutations on the clinical course of epithelial ovarian cancer (EOC). Patients and Methods: Clinicopathological variables and survival outcomes were compared among 53 primary EOC patients with pathogenic BRCA1 mutations in exons 1-11 (5’ mutations) and in exons 12-24 (3’ mutations). Results: BRCA1 5’ exonal mutations were found in 35 (66.0%) patients. The median follow-up period was 40 months. Clinicopathological variables remained unchanged between the two groups. Patients with 5’mutations had a significantly longer progression-free survival than those with C-terminal mutations (p=0.034), better predicting progression-free survival [2.923 (1.402-6.093), p=0.004], but not overall survival in cases of multiple relapses (p=0.497). Conclusion: N-terminal BRCA1 mutations in EOC patients are associated with favourable primary progression-free survival, a trend observed only in primary progression-free survival, not in overall survival.

Original language	English
Pages (from-to)	6947-6953
Number of pages	7
Journal	Anticancer research
Volume	38
Issue number	12
DOIs	https://doi.org/10.21873/anticanres.13073
Publication status	Published - 2018 Dec

Bibliographical note

Funding Information:
This study was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning (2014R1A1A1 A05002926 2017R1A2B4005503) and Faculty Research Grant of Yousei University College of Medicine (6-2018-0053). The funding body did not influence the study design, collection, analysis, or interpretation of data.

Publisher Copyright:
© 2018 International Institute of Anticancer Research. All rights reserved.

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.13073

Cite this

@article{b73e9b8a4b954a7f82d7ef2f886b3205,

title = "Distinct clinical courses of epithelial ovarian cancer with mutations in BRCA1 5{\textquoteright} and 3{\textquoteright} exons",

abstract = "Background/Aim: This study aimed to determine the effect of different BRCA1 exonal mutations on the clinical course of epithelial ovarian cancer (EOC). Patients and Methods: Clinicopathological variables and survival outcomes were compared among 53 primary EOC patients with pathogenic BRCA1 mutations in exons 1-11 (5{\textquoteright} mutations) and in exons 12-24 (3{\textquoteright} mutations). Results: BRCA1 5{\textquoteright} exonal mutations were found in 35 (66.0%) patients. The median follow-up period was 40 months. Clinicopathological variables remained unchanged between the two groups. Patients with 5{\textquoteright}mutations had a significantly longer progression-free survival than those with C-terminal mutations (p=0.034), better predicting progression-free survival [2.923 (1.402-6.093), p=0.004], but not overall survival in cases of multiple relapses (p=0.497). Conclusion: N-terminal BRCA1 mutations in EOC patients are associated with favourable primary progression-free survival, a trend observed only in primary progression-free survival, not in overall survival.",

author = "Eoh, {Kyung Jin} and Park, {Hyung Seok} and Park, {Ji Soo} and Lee, {Seung Tae} and Han, {Jung Woo} and Lee, {Jung Yun} and Sunghoon Kim and Kim, {Sang Wun} and Kim, {Young Tae} and Nam, {Eun Ji}",

note = "Funding Information: This study was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning (2014R1A1A1 A05002926 2017R1A2B4005503) and Faculty Research Grant of Yousei University College of Medicine (6-2018-0053). The funding body did not influence the study design, collection, analysis, or interpretation of data. Publisher Copyright: {\textcopyright} 2018 International Institute of Anticancer Research. All rights reserved.",

year = "2018",

month = dec,

doi = "10.21873/anticanres.13073",

language = "English",

volume = "38",

pages = "6947--6953",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "12",

}

TY - JOUR

T1 - Distinct clinical courses of epithelial ovarian cancer with mutations in BRCA1 5’ and 3’ exons

AU - Eoh, Kyung Jin

AU - Park, Hyung Seok

AU - Park, Ji Soo

AU - Lee, Seung Tae

AU - Han, Jung Woo

AU - Lee, Jung Yun

AU - Kim, Sunghoon

AU - Kim, Sang Wun

AU - Kim, Young Tae

AU - Nam, Eun Ji

N1 - Funding Information: This study was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning (2014R1A1A1 A05002926 2017R1A2B4005503) and Faculty Research Grant of Yousei University College of Medicine (6-2018-0053). The funding body did not influence the study design, collection, analysis, or interpretation of data. Publisher Copyright: © 2018 International Institute of Anticancer Research. All rights reserved.

PY - 2018/12

Y1 - 2018/12

N2 - Background/Aim: This study aimed to determine the effect of different BRCA1 exonal mutations on the clinical course of epithelial ovarian cancer (EOC). Patients and Methods: Clinicopathological variables and survival outcomes were compared among 53 primary EOC patients with pathogenic BRCA1 mutations in exons 1-11 (5’ mutations) and in exons 12-24 (3’ mutations). Results: BRCA1 5’ exonal mutations were found in 35 (66.0%) patients. The median follow-up period was 40 months. Clinicopathological variables remained unchanged between the two groups. Patients with 5’mutations had a significantly longer progression-free survival than those with C-terminal mutations (p=0.034), better predicting progression-free survival [2.923 (1.402-6.093), p=0.004], but not overall survival in cases of multiple relapses (p=0.497). Conclusion: N-terminal BRCA1 mutations in EOC patients are associated with favourable primary progression-free survival, a trend observed only in primary progression-free survival, not in overall survival.

AB - Background/Aim: This study aimed to determine the effect of different BRCA1 exonal mutations on the clinical course of epithelial ovarian cancer (EOC). Patients and Methods: Clinicopathological variables and survival outcomes were compared among 53 primary EOC patients with pathogenic BRCA1 mutations in exons 1-11 (5’ mutations) and in exons 12-24 (3’ mutations). Results: BRCA1 5’ exonal mutations were found in 35 (66.0%) patients. The median follow-up period was 40 months. Clinicopathological variables remained unchanged between the two groups. Patients with 5’mutations had a significantly longer progression-free survival than those with C-terminal mutations (p=0.034), better predicting progression-free survival [2.923 (1.402-6.093), p=0.004], but not overall survival in cases of multiple relapses (p=0.497). Conclusion: N-terminal BRCA1 mutations in EOC patients are associated with favourable primary progression-free survival, a trend observed only in primary progression-free survival, not in overall survival.

UR - http://www.scopus.com/inward/record.url?scp=85057538459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057538459&partnerID=8YFLogxK

U2 - 10.21873/anticanres.13073

DO - 10.21873/anticanres.13073

M3 - Article

C2 - 30504414

AN - SCOPUS:85057538459

SN - 0250-7005

VL - 38

SP - 6947

EP - 6953

JO - Anticancer Research

JF - Anticancer Research

IS - 12

ER -

Distinct clinical courses of epithelial ovarian cancer with mutations in BRCA1 5’ and 3’ exons

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this